1. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update. (10th December 2020) Authors: Bauman, Julie; Burris, Howard; Clarke, Jeffrey; Patel, Manish; Cho, Daniel; Gutierrez, Martin; Julian, Ricklie; Scott, Aaron; Cohen, Pamela; Frederick, Joshua; Robert-Tissot, Celine; Zhou, Honghong; Mody, Kinjal; Keating, Karen; Meehan, Robert; Gainor, Justin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A477 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update. (9th November 2020) Authors: Bauman, Julie; Burris, Howard; Clarke, Jeffrey; Patel, Manish; Cho, Daniel; Gutierrez, Martin; Julian, Ricklie; Scott, Aaron; Cohen, Pamela; Frederick, Joshua; Robert-Tissot, Celine; Zhou, Honghong; Mody, Kinjal; Keating, Karen; Meehan, Robert; Gainor, Justin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A846 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors. (7th November 2013) Authors: Ansell, Stephen; Northfelt, Donald; Flinn, Ian; Burris, Howard; Dinner, Shira; Villalobos, Victor; Sikic, Branimir; Pilja, Lana; Yellin, Michael; Keler, Tibor; Davis, Thomas Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors. (7th November 2013) Authors: Burris, Howard; Ansell, Stephen; Neumanitis, John; Weiss, Geoffrey; Sikic, Branimir; Northfelt, Donald; Pilja, Lana; Davis, Thomas; Yellin, Michael; Keler, Tibor; Bullock, Timothy Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC‐0994 in Patients with Advanced Solid Tumors. (28th May 2020) Authors: Weekes, Colin; Lockhart, Albert; LoRusso, Patricia; Murray, Elaine; Park, Erica; Tagen, Mike; Singh, Jatinder; Sarkar, Indrani; Mueller, Lars; Dokainish, Hatem; Shapiro, Geoffrey; Burris, Howard Journal: Oncologist Issue: Volume 25:Number 10(2020) Page Start: 833 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION. (5th November 2018) Authors: Mellinghoff, Ingo; Penas-Prado, Marta; Peters, Katherine; Cloughesy, Timothy; Burris, Howard; Maher, Elizabeth; Janku, Filip; Cote, Gregory; De La Fuente, Macarena; Clarke, Jennifer; Steelman, Lori; Le, Kha; Xu, Huansheng; Sonderfan, Alison; Hummel, Diana; Schoenfeld, Steven; Yen, Katharine; Pand... Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. Issue 1 (22nd August 2019) Authors: Naing, Aung; Infante, Jeffrey; Goel, Sanjay; Burris, Howard; Black, Chelsea; Marshall, Shannon; Achour, Ikbel; Barbee, Susannah; May, Rena; Morehouse, Chris; Pollizzi, Kristen; Song, Xuyang; Steele, Keith; Elgeioushi, Nairouz; Walcott, Farzana; Karakunnel, Joyson; LoRusso, Patricia; Weise, Amy; E... Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Issue 17 (13th June 2014) Authors: Kaufman, Peter A.; Bloom, Kenneth J.; Burris, Howard; Gralow, Julie R.; Mayer, Musa; Pegram, Mark; Rugo, Hope S.; Swain, Sandra M.; Yardley, Denise A.; Chau, Miu; Lalla, Deepa; Yoo, Bongin; Brammer, Melissa G.; Vogel, Charles L. Journal: Cancer Issue: Volume 120:Issue 17(2014) Page Start: 2657 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Issue 17 (13th June 2014) Authors: Kaufman, Peter A.; Bloom, Kenneth J.; Burris, Howard; Gralow, Julie R.; Mayer, Musa; Pegram, Mark; Rugo, Hope S.; Swain, Sandra M.; Yardley, Denise A.; Chau, Miu; Lalla, Deepa; Yoo, Bongin; Brammer, Melissa G.; Vogel, Charles L. Journal: Cancer Issue: Volume 120:Issue 17(2014) Page Start: 2657 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer. (14th December 2020) Authors: Sobrero, Alberto; Lenz, Heinz‐Josef; Eng, Cathy; Scheithauer, Werner; Middleton, Gary; Chen, Wenfeng; Esser, Regina; Nippgen, Johannes; Burris, Howard Journal: Oncologist Issue: Volume 26:Number 2(2021) Page Start: e261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗